(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) dropped by a staggering 19.06% in 5 sessions from $0.73 at -19.06, to $0.59 at 11:43 EST on Tuesday, after four sequential sessions in a row of losses. NASDAQ is rising 0.2% to $11,911.65, after two successive sessions in a row of losses.
Xenetic Biosciences’s last close was $0.59, 52.66% below its 52-week high of $1.25.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.34%.
Volume
Today’s last reported volume for Xenetic Biosciences is 47960 which is 37.34% below its average volume of 76552.
More news about Xenetic Biosciences (XBIO).
